文献速递自身免疫性与大疱性皮肤病

血清抗BP180 IgE自身抗体与大疱性类天疱疮疾病活动度的相关性

Correlation of Serum Levels of IgE Autoantibodies Against BP180 With Bullous Pemphigoid Disease Activity.
PubMed 文献 · JAMA Dermatol · 2017-01-01

这项病例对照队列研究纳入117例大疱性类天疱疮(BP)患者及多组对照,检测血清抗BP180 NC16A IgE。结果发现40.2%的BP患者该抗体阳性,其水平与总BPDAI评分相关(r=0.918;P=.06),且个体内随访中与BPDAI变化高度相关(r=0.983;P=.003)。抗BP180 IgE对诊断敏感性提升有限,但可能为抗IgE治疗提供依据。

要点

  • 40.2%的BP患者血清中可检测到抗BP180 NC16A IgE。
  • 抗BP180 NC16A IgE水平与个体内BPDAI变化高度相关(r=0.983)。
  • 抗BP180 IgE对BP诊断敏感性仅提升2.2%,诊断价值有限。

核心结论

  • 血清抗BP180 NC16A IgE对BP诊断价值有限,但可能指导抗IgE治疗决策。
  • 抗BP180 NC16A IgE水平与BP疾病活动度相关,支持其致病相关性。
  • 抗BP180 NC16A IgG与糜烂和水疱的发生相关,而与荨麻疹/红斑无显著关联。

研究设计与样本

  • 病例对照队列研究,纳入117例BP患者及多组对照(49例年龄匹配的非炎症性皮肤病、127例过敏检测者、30例天疱疮患者)。
  • 患者来自大学诊所,就诊时间为2008年1月1日至2014年7月31日。

主要发现

  • 117例BP患者中47例(40.2%)抗BP180 NC16A IgE阳性。
  • 抗BP180 NC16A IgE与总BPDAI相关(r=0.918;P=.06)。
  • 10例随机选取的BP患者个体内随访中,抗BP180 NC16A IgE水平与总BPDAI高度相关(r=0.983;P=.003)。
  • 抗BP180 NC16A IgE与荨麻疹或红斑性皮损无关联(r=0.481;P=.31)。
  • 抗BP180 NC16A IgG与糜烂和水疱发生相关(r=0.985;P=.006),与荨麻疹/红斑无关联(r=0.632;P=.23)。

关键数值与推荐

  • 抗BP180 NC16A IgE联合IgG ELISA仅将诊断敏感性提高2.2%(46份血清中1份)。
  • 抗BP180 NC16A IgE在BP患者中的阳性率为40.2%(47/117)。

临床怎么用

  • 抗BP180 IgE不作为BP常规诊断标志物,因敏感性提升有限。
  • 抗BP180 IgE水平可辅助评估疾病活动度,并可能为抗IgE治疗(如奥马珠单抗)提供依据。
  • 抗BP180 IgG与糜烂/水疱相关,提示不同抗体类型与临床表型相关。

局限性

  • 抗BP180 IgE与总BPDAI的相关性P=.06,未达统计学显著性。
  • 个体内相关性分析仅基于10例随机选取患者。
  • 研究为单中心队列,样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Bullous pemphigoid (BP) is by far the most frequent autoimmune blistering disease. The presence of IgE autoantibodies against the transmembrane protein BP antigen 2 (BP180, type XVII collagen) has previously been reported in 22% to 100% of BP serum samples, and the pathogenic relevance of anti-BP180 IgE has been suggested in various experimental models and by the successful use of omalizumab in individual patients with BP. OBJECTIVES: To determine the rate of anti-BP180-reactive IgE in BP, to evaluate the diagnostic relevance of anti-BP180 IgE in BP, and to correlate anti-BP180 IgE with disease activity and the clinical phenotype of patients with BP. DESIGN, SETTING, AND PARTICIPANTS: This case-control cohort study examined 3 groups of patients with BP. Sixty-five patients with BP underwent an enzyme-linked immunosorbent assay for IgE antibodies against the 16th noncollagenous domain of BP180 (NC16A); 52 consecutive patients with BP underwent clinical evaluation with the Bullous Pemphigoid Disease Activity Index (BPDAI); and 36 patients with BP without anti-BP180 NC16A IgG reactivity underwent evaluation of the diagnostic importance of serum anti-BP180 IgE. In addition, 49 age-matched control individuals with noninflammatory dermatoses, 127 controls undergoing allergy testing for IgE levels, and 30 controls with pemphigus vulgaris or pemphigus foliaceus were included for comparison. Patients were seen at a university clinic from January 1, 2008, to July 31, 2014. MAIN OUTCOMES AND MEASURES: Serum anti-BP180 NC16A IgE and IgG levels and BPDAI scores. RESULTS: Of 117 patients with BP (69 women and 48 men), anti-BP180 NC16A serum IgE was detected in 47 (40.2%) and correlated with disease activity as measured by total BPDAI (r = 0.918; P = .06). An intraindividual correlation of anti-BP180 NC16A serum levels with the total BPDAI was observed during the course of the disease in 10 randomly selected patients with BP (r = 0.983; P = .003). Although no association of circulating BP180 NC16A IgE antibodies with urticarial or erythematous lesions was observed (r = 0.481; P = .31), the presence of IgG anti-BP180 NC16A antibodies was associated with the occurrence of erosions and blisters (r = 0.985; P = .006) but not urticarial and erythematous lesions (r = 0.632; P = .23). Assaying for anti-BP180 IgE increased the diagnostic sensitivity by only 2.2% (1 of 46 serum samples) when combined with the IgG anti-BP180 enzyme-linked immunosorbent assay. CONCLUSIONS AND RELEVANCE: Although detection of serum anti-BP180 IgE is not of diagnostic importance, it may be relevant for therapeutic decisions (eg, the use of anti-IgE treatment). The correlation of serum anti-BP180 NC16A IgE levels with disease activity in patients with BP supports the notion that anti-BP180 IgE is of pathogenic relevance. Our observation that IgG anti-BP180 antibodies are related to the occurrence of blisters and erosions may encourage further studies on the association of fine autoantibody reactivities with clinical features of BP.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. van Beek N, Lüttmann N, Huebner F, et al. Correlation of Serum Levels of IgE Autoantibodies Against BP180 With Bullous Pemphigoid Disease Activity. JAMA Dermatol. 2017. PMID: 27829102. doi:10.1001/jamadermatol.2016.3357

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。